Claris Lifesciences Ahmedabad

Claris Lifesciences Limited (Claris) was the Holding Company of Claris Injectables Limited, a wholly-owned subsidiary dealing in Specialty Injectables business that was carved out in November 2014. Claris Injectables was sold to Baxter International Inc. in July 2017. Since its inception in 1999, Claris worked towards creating a niche in a highly-regulated business. Over a history of 17 years, we created nearly a billion-dollar valuation, with establishing world-class integrated business model that helped garner several stringent international regulatory approvals, including US FDA, MHRA (UK), TGA (Australia), MCC (South Africa), ANVISA (Brasil), INVIMA (Colombia), and GCC FDCA. Claris also entered a Joint Venture (JV) in August 2013 with Japanese companies Otsuka Pharmaceutical Factory, Inc. and Mitsui & Co. Ltd. for its Infusion business in India & emerging markets, selling 80% stake and creating JV company ‘Claris Otsuka Private Limited’ (COPL). Claris has completed the sale of its remaining stake to Otsuka, and exited from the JV. Coupled with the strength of technical know-how & professional expertise, Claris’ growth escalated through the diligent work carried out by the members to take the organisation to newer heights year-on-year. This proficiency was reconfirmed through the consecutive 8 wins as one of ‘India's Best Companies To Work For’ and one of the best companies in ‘Healthcare’ industry by The Economic Times and Great Place to Work® Institute, India. Parallel to striving for excellence, Claris serves as a socially responsible organisation, fulfilling goals beyond the business commitments. Hence, we always support and encourage various social causes aimed at promoting sports, health, education, and culture encompassing the broader spectrum of the society.